US health care giant Johnson & Johnson (NYSE: JN) subsidiary Janssen-Cilag International NV has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product.
The single tablet contains darunavir, a protease inhibitor developed by Janssen, with cobicistat, a pharmacokinetic enhancer or boosting agent, developed by US biotech firm Gilead Sciences (Nasdaq: GILD) for use in combination with other HIV-1 medicines.
Once-daily darunavir is marketed as Prezista in the European Union. If approved, the fixed-dose combination tablet will be marketed under a new brand name and will, for the first time, offer an option that eliminates the need to take a boosting agent in a separate tablet with once-daily darunavir.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze